Cancer, China

Oncology dominates a ‘Cambrian explosion’ in China’s drug pipeline as McKinsey guru bets on a burst of innovation

As the first wave of China’s homegrown new medicines begins to reach the market — from Chi-Med’s fruquintinib to Junshi’s toripalimab — they have also appeared to set the scene for the domination of oncology drugs in the biopharma pipeline.

In a post capturing Chinese biopharma’s “Cambrian Explosion” — a reference to the geological time period that marked a dramatic burst of evolutionary changes in life on Earth, courtesy of WuXi AppTec’s Steve Yang — Frank Le Deu, head of China healthcare at McKinsey, highlighted a classic herd effect:

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,800+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->